[CITATION][C] Efgartigimod: potential impact on IVIG therapy
JG Demain, FA Bonilla - The Journal of Allergy and Clinical …, 2022 - jaci-inpractice.org
I have a 70-year-old male patient with a history of myasthenia gravis diagnosed in 2011. He
was treated with mycophenolate and prednisone from 2011 to 2020, and large B-cell
lymphoma was diagnosed in early 2020 s/p rituximab, cyclophosphamide,
hydroxydaunorubicin hydrochloride, vincristine (Oncovin) and prednisone from June 2020 to
September 2020. He is currently in remission. Now being treated for myasthenia with
rituximab q6 months, the last dose was given in December 2021. He was on chronic …
was treated with mycophenolate and prednisone from 2011 to 2020, and large B-cell
lymphoma was diagnosed in early 2020 s/p rituximab, cyclophosphamide,
hydroxydaunorubicin hydrochloride, vincristine (Oncovin) and prednisone from June 2020 to
September 2020. He is currently in remission. Now being treated for myasthenia with
rituximab q6 months, the last dose was given in December 2021. He was on chronic …
